Search

Your search keyword '"Zaiou, Mohamed"' showing total 41 results
Start Over Author "Zaiou, Mohamed"
41 results on '"Zaiou, Mohamed"'

14. Expression of an additional cathelicidin antimicrobial peptide protects against bacterial skin infection

Author

Lee, Phillip H.A., Ohtake, Takaaki, Zaiou, Mohamed, Murakami, Masamoto, Rudisill, Jennifer A., Lin, Kenneth H., and Gallo, Richard L.

Subjects
Peptides -- Research, Peptides -- Genetic aspects, Bacterial skin diseases -- Research, Bacterial skin diseases -- Prevention, Bacterial skin diseases -- Genetic aspects, Science and technology
Abstract

Cathelicidin antimicrobial peptides are effectors of innate immune defense in mammals. Humans and mice have only one cathelicidin gene, whereas domesticated mammals such as the pig, cow, and horse have multiple cathelicidin genes. We hypothesized that the evolution of multiple cathelicidin genes provides these animals with enhanced resistance to infection. To test this, we investigated the effects of the addition of cathelicidins by combining synthetic cathelicidin peptides in vitro, by producing human keratinocytes that overexpress cathelicidins in culture, or by producing transgenic mice that constitutively overexpress cathelicidins in vivo. The porcine cathelicidin peptide PR-39 acted additively with human cathelicidin LL-37 to kill group A Streptococcus (GAS). Lentiviral delivery of PR-39 enhanced killing of GAS by human keratinocytes. Finally, transgenic mice expressing PR-39 under the influence of a K14 promoter showed increased resistance to GAS skin infection (50% smaller necrotic ulcers and 60% fewer surviving bacteria). Similarly constructed transgenic mice designed to overexpress their native cathelicidin did not show increased resistance. These findings demonstrate that targeted gene transfer of a xenobiotic cathelicidin confers resistance against infection and suggests the benefit of duplication and divergence in the evolution of antimicrobial peptides. innate immunity | keratinocyte

Published
2005

20. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18

Author

Koczulla, Rembert, von Degenfeld, Georges, Kupatt, Christian, Krötz, Florian, Zahler, Stefan, Gloe, Torsten, Issbrücker, Katja, Unterberger, Pia, Zaiou, Mohamed, Lebherz, Corinna, Karl, Alexander, Raake, Philip, Pfosser, Achim, Boekstegers, Peter, Welsch, Ulrich, Hiemstra, Pieter S., Vogelmeier, Claus, Gallo, Richard L., Clauss, Matthias, and Bals, Robert

Published
2003

32. Apolipoproteine A-IV : epart de la génétique et de l'environnement dans sa variabilité physiopathologique

Author

Zaiou, Mohamed, UL, Thèses, Université Henri Poincaré - Nancy 1 (UHP), Université Henri Poincaré - Nancy 1, and Sophie Visvikis-Siest

Subjects
Apolipoprotéine A4, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Polymorphisme génétique, Apolipoprotéine A, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Environnement
Abstract

Not available, Non disponible

Published
1993

41. The "forgotten" modified lipoprotein subspecies.

Author

Bakillah A and Zaiou M

Subjects
Cardiovascular Diseases blood, Cardiovascular Diseases diagnosis, Cholesterol blood, Cholesterol, LDL blood, Humans, Risk Factors, Biomarkers blood, Cardiovascular Diseases prevention & control, Lipoproteins blood
Abstract

Insights from preclinical and clinical studies have attempted to highlight the importance of modified lipoprotein particles in the pathogenesis of cardiovascular diseases (CVD). However, evidence is not conclusive. Since there is a relative dearth of clinical research in collecting useful information from traditional advanced lipoproteins testing, this present editorial introduces the aim of a special issue on modified lipoproteins as potential biomarkers for CVD. This issue aims at gathering a selection of insightful articles that address major challenges related to potential clinical use of modified lipoproteins as new CVD biomarkers. The editors seek to promote better mobilization of lipoproteins measurement for the pursuit of sustainable CVD clinical outcome and development of potential biomarkers. Knowledge and progress in this particular field will certainly help answering questions about clinical relevance of circulating modified lipoprotein subspecies and their potential use for better patient care and disease prevention. We hope that, when taken together, the focus on modified lipoproteins will stimulate new vision and reveal study key aspects for better clinical data outcome and more effective therapeutic strategies.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results